IART
NASDAQIntegra LifeSciences Holdings Corporation
SectorHealth CareIndustryMedical/Dental Instruments
Price$19.24-0.40 (-2.04%)
01:30 PM07:45 PM
News · 26 weeks58-10%
2026-01-182026-07-12
Mix3690d
- Insider12(33%)
- Other9(25%)
- SEC Filings6(17%)
- Earnings4(11%)
- Analyst3(8%)
- Leadership2(6%)
Latest news
25 items- PRIntegra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the
- ANALYSTBMO Capital Markets initiated coverage on Integra with a new price targetBMO Capital Markets initiated coverage of Integra with a rating of Market Perform and set a new price target of $19.00
- PROne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsIssued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P
- INSIDERSVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by EVP & President, SS Singh Harvinder4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by EVP & President, TR&DT Davis Robert T. Jr.4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDEREVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 5,226 shares, decreasing direct ownership by 10% to 45,263 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- PRIntegra LifeSciences Appoints Topaz Kirlew Chief Regulatory OfficerPRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide. Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed activ
- PRIntegra LifeSciences Announces Key Executive AppointmentsPRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (NASDAQ:IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy. Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Ki
- ANALYSTIntegra upgraded by Argus with a new price targetArgus upgraded Integra from Hold to Buy and set a new price target of $25.00
- PRThe Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a problem to be solved. When skin, bone, or soft tissue is destroyed by injury, surgery, disease, or age, the standard of care has largely been about coverage and replacement — grafts, implants, fillers,
- PRIntegra LifeSciences to Present at the 2026 Truist Securities MedTech ConferencePRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and ti
- PRA Fresh FDA Catalyst Is Putting Regenerative Wound Care in FocusNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
- INSIDERSEC Form 4 filed by EVP & Chief Commercial Officer Mcbreen Michael J.4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Essig Stuart4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- PRThe Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsIssued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
- PRIntegra LifeSciences to Present at the 2026 Jefferies Global Healthcare ConferencePRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fi
- SECSEC Form SD filed by Integra LifeSciences Holdings CorporationSD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- ANALYSTIntegra upgraded by Citigroup with a new price targetCitigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00
- PRRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItIssued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
- INSIDERDirector Hill Barbara B was granted 24,338 shares, increasing direct ownership by 19% to 151,191 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERDirector Bradley Keith covered exercise/tax liability with 882 shares, decreasing direct ownership by 0.99% to 88,254 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Clay Shaundra4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Graves Jeffrey A4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by Director Lo Renee Wonlai4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
IART FAQ
6 questionsWhat does Integra LifeSciences Holdings Corporation do?
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps...Where does IART stock trade?
Integra LifeSciences Holdings Corporation (IART) is listed on NASDAQ.What sector and industry is IART in?
Integra LifeSciences Holdings Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about IART?
Integra LifeSciences Holdings Corporation has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform with a $1900.00 price target on 2026-07-09. Recent price targets range from $1600.00 to $2500.00.What companies are similar to IART?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare IART side-by-side with any of them on Quantisnow.How can I track IART on Quantisnow?
Quantisnow aggregates Integra LifeSciences Holdings Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IART to receive live email and push alerts on every new disclosure.